Medical and surgical palliative care of patients with urological malignancies

Journal of Urology

Volumn 174, Issue 4 I, 2005, Pages 1177-1182

  Ok, Joon Ha ^a   Meyers, Frederick J ^b   Evans, Christopher P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bladder neoplasms; Kidney neoplasms; Pain; Palliative care; Prostatic neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; AMMONIUM SULFATE; ANALGESIC AGENT; CISPLATIN; CODEINE; CORTICOSTEROID; DIHYDROCODEINE; FENTANYL; FORMALDEHYDE; HYDROCODONE; HYDROCORTISONE; HYDROMORPHONE; LAXATIVE; LEVORPHANOL; METHADONE; METHOTREXATE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PREDNISONE; PROGESTERONE; SILVER NITRATE; STRONTIUM 89; ZOLEDRONIC ACID;

BLADDER CANCER; BLADDER CATHETERIZATION; BLADDER PERFORATION; BLEEDING; BONE PAIN; CANCER INVASION; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CONSTIPATION; FIBROSIS; HEALTH CARE QUALITY; HUMAN; KIDNEY CANCER; MORBIDITY; OUTCOMES RESEARCH; PELVIS PAIN SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPINAL CORD COMPRESSION; SYSTEMATIC REVIEW; URETER OBSTRUCTION; URINARY TRACT SURGERY; UROGENITAL TRACT CANCER;

EID: 24944569249     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000173077.84274.01     Document Type: Review

References (48)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E. and Thun, M. J.: Cancer statistics, 2003. CA Cancer J Clin, 53: 5, 2003
2. Surveillance, Epidemiology, and End Results Program 1970-1996, Division of Cancer Control and Population Sciences, National Institutes of Health. Washington, D. C.: American Cancer Society, 2000
3. Meyers, F. J. and Linder, J.: Simultaneous care: disease treatment and palliative care throughout illness. J Clin Oncol, 21: 1412, 2003
4. Scher, H. I., Zhang, Z. F., Nanus, D. and Kelly, W. K.: Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology, 47: 61, 1996
5. Coleman, R. E.: Skeletal complications of malignancy. Cancer, 80: 1588, 1997
6. Honore, P., Rogers, S. D., Schwei, M. J., Salak-Johnson, J. L., Luger, N. M., Sabino, M. C. et al: Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience, 98: 585, 2000
7. Tong, D., Gillick, L. and Hendrickson, F. R.: The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer, 50: 893, 1982
8. Brundage, M. D., Crook, J. M. and Lukka, H.: Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group. Cancer Prev Control, 2: 79, 1998
9. Patel, B. R. and Flowers, W. M., Jr.: Systemic radionuclide therapy with strontium chloride Sr 89 for painful skeletal metastases in prostate and breast cancer. South Med J, 90: 506, 1997
10. Robinson, R. G., Preston, D. F., Schiefelbein, M. and Baxter, K. G.: Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA, 274: 420, 1995
11. Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N. et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 351: 1502, 2004
12. Lipton, A., Small, E., Saad, F., Gleason, D., Gordon, D., Smith, M. et al: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest, suppl., 20: 45, 2002
13. Rodan, G. A. and Reszka, A. A.: Bisphosphonate mechanism of action. Curr Mol Med, 2: 571, 2002
14. Green, J. R., Muller, K. and Jaeggi, K. A.: Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res, 9: 745, 1994
15. Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L. et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst, 94: 1458, 2002
16. Smith, M. R., Eastham, J., Gleason, D. M., Shasha, D., Tchekmedyian, S. and Zinner, N.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol, 169: 2008, 2003
17. Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Anesthesiology, 84: 1243, 1996
18. Kamat, A. M., Huang, S. F., Bermejo, C. E., Roeser, C. J., Pettaway, C. A., Pisters, P. W. T. et al: Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol, 170: 1868, 2003
19. Surya, B. V. and Provet, J. A.: Manifestations of advanced prostate cancer: prognosis and treatment. J Urol, 142: 921, 1989
20. Saitoh, H., Yoshida, K., Uchijima, Y., Kobayashi, N., Suwata, J. and Kamata, S.: Two different lymph node metastatic patterns of a prostatic cancer. Cancer, 65: 1843, 1990
21. Michigan, S. and Catalona, W. J.: Ureteral obstruction from prostatic carcinoma: response to endocrine and radiation therapy. J Urol, 118: 733, 1977
22. Megalli, M. R., Gursel, E. O., Demirag, H., Veenema, R. J. and Guttman, R.: External radiotherapy in ureteral obstruction secondary to locally invasive prostatic cancer. Urology, 3: 562, 1974
23. Rosenthal, M. A., Rosen, D., Raghavan, D., Leicester, J., Duval, P., Besser, M. et al: Spinal cord compression in prostate cancer. A 10-year experience. Br J Urol, 69: 530, 1992
24. Grossman, S. A. and Lossignol, D.: Diagnosis and treatment of epidural metastases. Oncol (Huntingt), 4: 47, 1990
25. Loblaw, D. A. and Laperriere, N. J.: Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol, 16: 1613, 1998
26. Bach, F., Larsen, B. H., Rohde, K., Borgesen, S. E., Gjerris, F., Boge-Rasmussen, T. et al: Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien), 107: 37, 1990
27. Gilbert, R. W., Kim, J. H. and Posner, J. B.: Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol, 3: 40, 1978
28. Welch, W. C. and Jacobs, G. B.: Surgery for metastatic spinal disease. J Neurooncol, 23: 163, 1995
29. Smith, E. M., Hampel, N., Ruff, R. L., Bodner, D. R. and Resnick, M. I.: Spinal cord compression secondary to prostate carcinoma: treatment and prognosis. J Urol, 149: 330, 1993
30. Huddart, R. A., Rajan, B., Law, M., Meyer, L. and Dearnaley, D. P.: Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. Radiother Oncol, 44: 229, 1997
31. Goel, A. K., Rao, M. S., Bhagwat, A. G., Vaidyanathan, S., Goswami, A. K. and Sen, T. K.: Intravesical irrigation with alum for the control of massive bladder hemorrhage. J Urol, 133: 956, 1985
32. Donahue, L. A. and Frank, I. N.: Intravesical formalin for hemorrhagic cystitis: analysis of therapy. J Urol, 141: 809, 1989
33. Sarnak, M. J., Long, J. and King, A. J.: Intravesicular formaldehyde instillation and renal complications. Clin Nephrol, 51: 122, 1999
34. Srinivasan, V., Brown, C. H. and Turner, A. G.: A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol), 6: 11, 1994
35. Salminen, E.: Unconventional fractionation for palliative radiotherapy of urinary bladder cancer. A retrospective review of 94 patients. Acta Oncol, 31: 449, 1992
36. Motzer, R. J., Bander, N. H. and Nanus, D. M.: Renal-cell carcinoma. N Engl J Med, 335: 865, 1996
37. Janzen, N. K., Kim, H. L., Figlin, R. A. and Belldegrun, A. S.: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am, 30: 843, 2003
38. Kaiman, D. and Varenhorst, E.: The role of arterial embolization in renal cell carcinoma. Scand J Urol Nephrol, 33: 162, 1999
39. Wood, C. G.: The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am, 30: 581, 2003
40. Chan, A. L., Yoneda, K. Y., Allen, R. P. and Albertson, T. E.: Advances in the management of endobronchial lung malignancies. Curr Opin Pulm Med, 9: 301, 2003
41. Cancer Pain Relief and Palliative Care. Geneva, Switzerland: World Health Organization, Techical Report Series No. 804, p. 11, 1990
42. Weisman, A. D. and Worden, J. W.: The existential plight in cancer: significance of the first 100 days. Int J Psychiatry Med, 7: 1, 1976
43. Barakat, L. P., Kazak, A. E., Meadows, A. T., Casey, R., Meeske, K. and Stuber, M. L.: Families surviving childhood cancer: a comparison of posttraumatic stress symptoms with families of healthy children. J Pediatr Psychol, 22: 843, 1997
44. Toseland, R. W., Blanchard, C. G. and McCallion, P.: A problem solving intervention for caregivers of cancer patients. Soc Sci Med, 40: 517, 1995
45. Zabora, J. R. and Smith, E. D.: Family dysfunction and the cancer patient: early recognition and intervention. Oncology (Huntingt), 5: 31, 1991
46. Cancer care during the last phase of life. J Clin Oncol, 16: 1986, 1998
47. Christakis, N. A. and Escarce, J. J.: Survival of Medicare patients after enrollment in hospice programs. N Engl J Med, 335: 172, 1996
48. Haupt, B. J.: Characteristics of hospice care discharges and their length of service: United States, 2000. Vital Health Stat, 154: 1, 2003